Using a model of MSS-CRC, we demonstrated that loss of Atg16l1 drove productive cellular immunity against MSS-CRC tumors, enhanced IFN signaling, and accelerated programmed cell death. The gene discussed is ATG16L1; the disease is colorectal carcinoma.